8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C

Summary

This is open-label, randomized, multicentre study to compare the efficacy and safety of the 8-week versus 12-week of SOF-RVD combination treatment for non-cirrhotic chronic hepatitis C patients. All the recruited subjects will receive the treatment accordingly and be followed up for 24 weeks following the completion of treatment.

Timeline

Start

2021-03-23

Primary completion

2023-12-29

Completion

2024-03-15

Outcome

Met primary endpoint

paper difference: -0.04%; 90% CI: -4.94% to 4.85%; P = 0.047), demonstrating non-inferiority. PMID 42140479 ↗

Publications

• Muhamad NA, Mohd Dali NS, Maamor NH, Rosli IA, Leman FN, Awaluddin SM, Chan HK, Mohd Zin R, Abu Hassan MR. Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial. BMC Infect Dis. 2026 Jun 11. doi: 10.1186/s12879-026-13741-5. Online ahead of print.
• Abu Hassan MR, Muhamad NA, Mohammed NS, Mohd Suan MA, Zulkifli Supramaniam DN, Jogulu SR, Md Salleh MF, Soelar SA, Rosli IA, Leman FN, Mohd Dali NS, Maamor NH, Ngah NF, Chan HK; EASE Trial Group. A Multicenter, open-label, randomized, non-inferiority trial of 8 versus 12 weeks of sofosbuvir/ravidasvir treatment in non-cirrhotic patients with chronic hepatitis C virus infection (EASE trial). Int J Infect Dis. 2026 Aug;169:108788. doi: 10.1016/j.ijid.2026.108788. Epub 2026 May 14.

Drugs

Indications